

November 14, 2025

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

**Notice of Extension of Investigator-Initiated Phase I/II Clinical Trial Period for PPMX-T003 in Aggressive NK-Cell Leukemia (ANKL)**

We hereby announce that the clinical trial period for the investigator-initiated Phase I/II clinical trial (the “Trial”) using PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody under development by our company, as a therapeutic agent for aggressive NK-cell leukemia (ANKL), will be extended until March 31, 2027.

As the target disease for the Trial is an ultra-rare condition, enrollment has been challenging, and four patients have been enrolled to date. The coordinating investigator has determined that completion by March 31, 2026 would be difficult, and the extension of the trial period to March 31, 2027 has been registered in the jRCT (Japan Registry of Clinical Trials).

The impact of this matter on our business performance for the next fiscal year and beyond is currently under review. We will promptly disclose any material information following the completion of our review.

End